Refining the Policy for Timing of Kidney Transplant Waitlist Qualification. by Lee, Benjamin J et al.
UCSF
UC San Francisco Previously Published Works
Title
Refining the Policy for Timing of Kidney Transplant Waitlist Qualification.
Permalink
https://escholarship.org/uc/item/3b59x2j2
Journal
Transplantation Direct, 3(8)
ISSN
2373-8731
Authors
Lee, Benjamin J
McCulloch, Charles E
Grimes, Barbara A
et al.
Publication Date
2017-08-01
DOI
10.1097/TXD.0000000000000706
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Kidney TransplantationRefining the Policy for Timing of Kidney
Transplant Waitlist Qualification
Benjamin J. Lee, MD,1 Charles E. McCulloch, PhD,2 Barbara A. Grimes, PhD,2 Sindhu Chandran, MD,1
Isabel Elaine Allen, PhD,2 Cynthia Delgado, MD,1,3 and Chi-yuan Hsu, MD, MSc1Background. Earlier qualification for the kidney transplant waitlist expedites transplant and is therefore associated with im-
proved outcomes. U.S. Organ Procurement and Transplantation Network policies state that “measured or calculated creatinine
clearance or glomerular filtration rate less than or equal to 20 mL/min” triggers waitlist time accrual. The choice of qualification
method is somewhat arbitrary, and the policy implies that decline in renal function is monotonic.Methods. (1) We used survival
analysis to quantify temporal differences in waitlist qualification by applying 3 kidney-function-estimating equations (Cockcroft-
Gault, Modification of Diet in Renal Disease study, Chronic Kidney Disease Epidemiology Collaboration) to serial creatinine mea-
surements from 3 patient cohorts: 1 of waitlisted patients at a major U.S. academic center and 2 national, multicenter cohorts
of chronic kidney disease patients (African American Study of Kidney Disease and Hypertension, Modification of Diet in Renal Dis-
ease). (2) Survival analysis assessed whether requiring patients to demonstrate persistently reduced renal function on 2 occasions
at least 90 days apart would meaningfully change qualification order.Results.On average, time to waitlist qualification would be
delayed on the order of 1 to 2 years by using calculated creatinine clearance (per the Cockcroft-Gault equation). Compared with
current policy, requiring demonstration of persistently reduced renal function delayed qualification by 0.6 to 2.1 years and caused
40% to 50%of patients to switch the order in which they qualify by 6months or more.Conclusions.The kidney transplantation
policies should be revised, such that timing of waitlist qualification is more standardized. We suggest that mention of using calcu-
lated creatinine clearance be dropped from the Organ Procurement and Transplantation Network policy wording and the units to
quantify kidney function be changed tomL/min per 1.73m2. Some consideration should be given towhether requiring persistently
reduced renal function would better identify patients most likely to benefit from earlier waitlist qualification.
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2 Transplantation DIRECT ■ 2017 www.transplantationdirect.comRenal transplantation is the treatment of choice forend-stage renal disease. Compared with waitlisted,
dialysis-dependent patients, transplanted patients have lower
long-term mortality and increased life expectancy—by up to
10 years (depending on patient age and comorbidities)1-4—
and improved quality of life.5 Accounting for 11% of all de-
ceased donor transplants in the United States from 2003 to
2012,6 preemptive kidney transplantation (ie, done before
initiation of maintenance dialysis), is associatedwith an addi-
tional 26% to 31% reduction in mortality relative to non-
preemptive transplant recipients, as well as lower rates of
delayed graft function and graft failure.7
Observed mortality while accruing time on the transplant
waitlist is high: recent estimates are 4% to 6% per year.8 Be-
cause timing of waitlist qualification affects the likelihood of
preemptive transplantation, being placed on the waitlist ear-
lier versus later has important clinical consequences. In addi-
tion, longer duration of pretransplant dialysis is associated
with a progressive increase in patient death and graft loss
posttransplant.9-12 Yet over the last decade, 79% of deceased
donor kidney transplant recipients were dialyzed for more
than 2 years, and only 6% of deceased donor kidney trans-
plant recipients were dialyzed for less than 1 year.6 Thus,
even among non-preemptively transplanted patients, qualify-
ing for the waitlist earlier reduces duration of pretransplant
dialysis and may improve outcomes.
Therefore, factors that influence timing of waitlist qualifi-
cation are important and deserve scrutiny. According to cur-
rent U.S. Organ Procurement and Transplantation Network
(OPTN) rules, patients with advanced chronic kidney disease
(CKD) begin accruing time on the kidney transplant waitlist
when renal function declines beyond a threshold defined as
“measured or calculated creatinine clearance (CrCl) or glomer-
ular filtration rate (GFR) less than or equal to 20 mL/min”
(or when chronic maintenance dialysis is initiated).13
The Cockcroft-Gault equation estimates CrCl (in mL/min
from serum creatinine, age, sex, and weight).14 Since 1999,
the Cockcroft-Gault equation has been largely replaced in
daily clinical practice (with the exception of medication dos-
ing) by the Modification of Diet in Renal Disease (MDRD)
study equation, which estimates GFR (in mL/min per 1.73 m2
from serum creatinine, age, sex, and race).15 More recently,
the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation (first published in 2009), which also es-
timates GFR (in mL/min per 1.73 m2 using the same vari-
ables as the MDRD study equation), has been increasingly
adopted in clinical practice.16
Prior studies have consistently shown that the Cockcroft-
Gault equation overestimates renal function compared with
the MDRD study and CKD-EPI equations in advanced
CKD patients.17-20 This fact is not surprising, because CrCl
is systematically higher than GFR due to tubular secretion
of creatinine.21,22 Therefore, using the Cockcroft-Gault
equation may disadvantage patients for transplant waitlist
qualification, but whether such a delay is clinically meaning-
ful is unknown. Furthermore, by not requiring persistence of
CrCl or estimated GFR (eGFR) being “≤20 mL/min” to be-
gin waitlist time accrual, the current policy implicitly assumes
that decline in renal function is monotonic. This concept had
been a widely accepted paradigm of the natural history of re-
nal disease progression, as formulated, for example, in a sem-
inal article by Mitch et al23 published in 1976 reporting thatfor most patients, reciprocal serum-creatinine concentration
declined linearly with time. However, recent studies demon-
strate that estimated GFR trajectories among CKD patients
are often not linear but instead vary between periods of rapid
decline versus extended stability.24
The goal of this study was to scrutinize the current OPTN
policies for timing of kidney transplant waitlist qualifica-
tion more closely, specifically for the approximately 20%
of waitlisted patients who are listed preemptively (>57 000
patients from 2000 to 2009).25 Given that calculated CrCl
(by the Cockcroft-Gault equation) tends to overestimate re-
nal function as compared with other creatinine-based renal-
function equations (calculated GFR by the MDRD and
CKD-EPI equations), we compared the equations' relative
performance in 3 actual patient cohorts to assess whether
the magnitude of difference in timing of waitlist qualification
is clinically meaningful. We also examined the impact of re-
quiring patients to demonstrate persistently low renal func-
tion to assess whether such a requirement may more
appropriately prioritize which patients are in greater need
for transplant. If choice of qualification method or incorrect
assumption about the trajectory of renal function decline al-
ters the timing of waitlist qualification by a large amount of
time, the clinical implications are considerable for this patient
population with high mortality risk.MATERIALS AND METHODS
The Cockcroft-Gault, MDRD study, and CKD-EPI equa-
tions have been previously described (SDC, http://links.
lww.com/TXD/A49).14-16 We assessed the impact of using
different renal function equations to determine waitlist qual-
ification by applying the equations to serial creatinine mea-
surements from 3 actual patient cohorts.
University of California, San Francisco Cohort
We examined patients from the University of California,
San Francisco (UCSF) General Nephrology faculty practice
who were placed on the UCSF adult kidney transplant
waiting list from July 1, 1999, to June 30, 2012, and who
had laboratory data in the UCSF electronic medical record
(n = 224). The following datawere extracted for each patient:
serial serum creatininemeasurements and serial bodyweights
from the earliest available date in the UCSF electronic medi-
cal record through September 7, 2013 (the date our data
were extracted), height, sex, and race (African American,
white, or other). To remove serum creatinine values associ-
ated with potential acute kidney injury, values for which
there was another creatinine measured within 1 week were
excluded.26 Of 224 patients in the total UCSF cohort,
9 patients were excluded because of missing body weights
(precluding calculation of CrCl by Cockcroft-Gault), leaving
215 patients for analysis.
African American Study of Kidney Disease and
Hypertension Cohort
African American Study of Kidney Disease and Hyperten-
sion (AASK) was an NIH-sponsored randomized controlled
study of AfricanAmerican patients (n = 1094) with hyperten-
sive CKD (GFR, 20-65 mL/min per 1.73 m2 as measured by
[125I] iothalamate clearance) who were initially enrolled into
“intensive” or “standard” blood pressure control groups
(and assigned 1 of 3 antihypertensive drug classes) and
© 2017 Wolters Kluwer Lee et al 3subsequently followed as a cohort.27-29 Because antihyper-
tensive medication initiation at the time of enrollment
caused acute changes in GFR,27 only serial creatinine mea-
surements during the chronic slope phase of the study were
analyzed. Per the AASK protocol, creatinine was checked at 3
and 6 months postrandomization, and followed up every
6months thereafter.27Of the 1094patients in theAASKcohort,
only 1059 had visits at 3 months postrandomization or later;
2 patients were subsequently excluded because of missing body
weights; therefore, 1057 patients remained for analysis.
Modification of Diet in Renal Disease Cohort
The MDRD study was an NIH-sponsored randomized
controlled study that evaluated the effect of dietary protein
restriction and strict blood pressure control on progression
of renal disease in 840 CKD patients (GFR <70 mL/min per
1.73 m2 as measured by [125I] iothalamate clearance).30,31
Similar to the AASK cohort, to avoid acute effects of antihy-
pertensive medication initiation, we only examined serial cre-
atinine measurements from the chronic slope phase of the
study. Per theMDRD study protocol, creatinine was checked
at 4 months postrandomization and then every 4 months
thereafter.31 Seventeen patients did not have any serum creat-
inine measurements and were excluded from analysis, leav-
ing 823 patients for analysis.
Statistical Analysis
For every patient in the 3 study populations, we applied
the 3 creatinine-based equations (Cockcroft-Gault, MDRD
study, and CKD-EPI) to calculate renal function (CrCl for
Cockcroft-Gault, eGFR for MDRD study and CKD-EPI)
for each creatinine measurement. The body weight used for
the Cockcroft-Gault equation was the last weight measured
on or before the date of creatininemeasurement (ie, last value
carried forward if not measured concurrently). For the few
creatinine measurements where there were no prior or con-
current weights recorded, the first recorded weight was used.
The date at which each patient's CrCl or eGFR fell to
≤20mL/min≤20 or 20mL/min per 1.73 m2 was determined
for each equation. Although CrCl and eGFR and use differ-
ent units, direct comparison is what is used under current
OPTN policy.
Time-to-Waitlist-Qualification Analysis
We used survival analysis to quantify the differences in me-
dian time to waitlist qualification (ie, median time to≤20) by
equation for each cohort. Time to waitlist qualification was
defined for the UCSF cohort as time from first available se-
rum creatinine record for each patient in the UCSF electronic
medical record. Time to waitlist qualification was defined for
the AASK and MDRD cohorts as time from the first follow-
up visit during the chronic-slope periods postrandomization.
Patients who were not observed to qualify by 1 of the equa-
tions were censored for the analysis limited to that equation.
Participants censored by all 3 equations were excluded from
this analysis since the research question is not relevant to
those persons (this situation occurred in 19 of 215 patients
for UCSF cohort, 787 of 1057 patients for AASK cohort,
406 of 823 patients for MDRD cohort). That is, the purpose
of our analysis was to compare differences between equa-
tions; patients who did not qualify by any equation would
not contribute any information to this analysis, as theoutcome is not “survival time to waitlist qualification” in
and of itself. For each cohort, Kaplan-Meier curves for time
to waitlist qualification were constructed for each equation.
The Kaplan-Meier method estimates cumulative incidence
of an event (in this case, waitlist qualification) by splitting
follow-up time into discrete periods and dividing the num-
ber of events by the number of at-risk individuals for each
period.32 A Kaplan-Meier curve is a step function plotting
cumulative incidence over follow-up time. Median time to
event (point at which the KM curve crossed the 50% sur-
vival point) was then derived for each equation in each co-
hort (3 equations applied to 3 cohorts yielded 9 median
times to event). Within each cohort, to compare median
time to waitlist qualification across eGFR equations, we
used bootstrapping33 to generate P values and confidence
intervals.
Persistently Low-Function Analysis
To assess whether requiring patients to demonstrate persis-
tently low renal function would meaningfully change waitlist
qualification, we compared time to qualification as defined
by 2 different rules: (1) at first CKD-EPI–derived eGFR of
20mL/min per 1.73m2 or less, regardless of subsequent mea-
surements (current paradigm) and (2) at second CKD-EPI–
derived eGFR of 20 mL/min per 1.73 m2 or less given a prior
eGFR of 20 mL/min per 1.73 m2 or less at least 3 months be-
fore (akin to the definition of CKD34). The start times, cen-
soring rules, and patient cohorts were the same as described
above. Kaplan-Meier curves for time to waitlist qualification
were constructed for each cohort. To compare median time
with waitlist qualification across rules for waitlisting, we
used bootstrapping33 to generate P values and confidence in-
tervals. Within each cohort, we identified all instances where
2 patients switched the order in which they qualified for the
waitlist by a magnitude of 6 months or more; the number
of unique patients affected by these switches was noted for
each cohort.
The study was conducted in accordance with the Dec-
larations of Helsinki and Istanbul. The study design and
methods were approved by the UCSF Institutional Review
Board (IRB 12-10371), which waived the need for informed
consent because the study involved no more than minimal
risk to subjects. Analyses were conducted using SAS version
9.4 (Cary, NC).RESULTS
Cohort Characteristics
Table 1 shows selected characteristics for the 3 cohorts
studied. The AASK andMDRD cohorts have been described
in detail previously.27,30 Of note, all patients in AASK were
black, whereas the UCSF and MDRD cohorts were predom-
inantly nonblack. For the UCSF cohort, the median MDRD
study equation eGFR for the first creatinine measurement
in the UCSF electronic medical recordwas 28.8 (interquartile
range [IQR], 14.3-57.5) mL/min per 1.73 m2. (The MDRD
study equation was what was used by the UCSF Medical
Center lab at the time the measurements were collected.)
The median eGFRs (calculated using theMDRD study equa-
tion) at time of enrollment were 42.3 mL/min per 1.73 m2
(IQR, 31.3-52.1 mL/min per 1.73 m2) for AASK and 32.7
TABLE 1.
Cohort characteristics
UCSF
(n = 224)
AASKa
(n = 1094)
MDRDa
(n = 840)
Mean age, y 47.0 54.6 51.5
Male sex, % 58.7 61.1 60.5
Race, %
Nonblack 84.8 0.0 92.1
Black 15.2 100.0 7.9
Mean BMI, kg/m2 27.4 30.6 27.1
Diagnosis of hypertension, % 80.9 100.0 86.2
Mean blood pressure, mm Hg
Systolic 137.7 150.3 134.4
Diastolic 77.4 95.5 81.9
Diagnosis of diabetes mellitus, % 30.0 0.0 5.1 b
Median (IQR) serum Cr, mg/dL 2.1 (1.3-4.4) 1.8 (1.5-2.4) 2.1 (1.6-2.8)
Median (IQR) eGFRc, mL/min
per 1.73 m2
28.8 (14.3-57.5) 42.3 (31.3-52.1) 32.7 (24.1-43.1)
a AASK and MDRD data from entire baseline cohort at time of randomization.
b Noninsulin-dependent diabetic nephropathy; excluded insulin-dependent diabetes.
c Calculated using MDRD study equation.
4 Transplantation DIRECT ■ 2017 www.transplantationdirect.commL/min per 1.73 m2 (IQR, 24.1-43.1 mL/min per 1.73 m2)
for the MDRD cohort.
Time-to-Waitlist Qualification Analysis
Among patients for whom at least 1 equation yielded
an observed qualification date (UCSF, n = 196; AASK,
n = 270; MDRD, n = 417), the magnitudes of time difference
between qualification dates generated by survival analyses
are shown in Table 2. TheMDRD study and CKD-EPI equa-
tions gave similar waitlist qualification dates, but Cockcroft-
Gault consistently disadvantaged patients. The difference in
median time to waitlist qualification (not median time on
the waitlist) for the Cockcroft-Gault equation as compared
with the MDRD study equation was 715.5 days (1.96 years)
later for the UCSF cohort, 711 days (1.95 years) later for the
AASK cohort, and 466 days (1.28 years) later for theMDRD
cohort. In other words, on average, time to waitlist qualifica-
tion would be delayed on the order of 1 to 2 years by using
calculated CrCl rather than calculated GFR. Between the
MDRD study equation and CKD-EPI equation, on the other
hand, differences in median times to waitlist qualification
were all less than 1 month for all cohorts.
Persistently Low-Function Analysis
Survival analyses assessing timing of waitlist qualification
under an alternative rule requiring patients to demonstrate
eGFR ≤20 mL/min per 1.73 m2 on 2 occurrences at leastTABLE 2.
Median time (95% CI) in years to waitlist qualification by equatio
Cockcroft-Gault MDRD CKD-EPI
UCSF cohort 2.93 (1.50-4.32) 0.97 (0.24-2.29) 1.04 (0.31-2.38)
AASK cohort 3.20 (2.72-3.70) 1.25 (0.83-1.70) 1.23 (0.80-1.42)
MDRD cohort 1.58 (1.34-2.01) 0.30 (a, 0.35) 0.33 (a, 0.37)
Time to waitlist qualification was defined for the UCSF cohort as time from first available serum creatinine rec
and 4 months postrandomization, respectively.
a Censored.3 months apart as compared with current policies are
shown in Table 3. Using the CKD-EPI equation, requiring
demonstration of persistently low renal function delayed me-
dian time to waitlist qualification by 770 days (2.1 years),
539 days (1.5 years), and 234 days (0.6 years) in the UCSF,
AASK, andMDRD cohorts, respectively. Furthermore, chang-
ing to rule 2 delayed waitlist qualification by at least 6 months
in a large majority of the patients: 181 (92.3%) of 196 UCSF
cohort patients, 247 (91.5%) of 270 AASK cohort patients,
and 366 (87.8%) of 417MDRDcohort patients. In addition,
implementing such an alternative rule caused a significant
number of patients to switch the order in which they would
qualify. 53.1% of UCSF cohort patients switched positions
with at least 1 other patient by 6months ormore; the alterna-
tive rule similarly affected 47.8% of the AASK cohort and
40.5% of the MDRD cohort.
DISCUSSION
The U.S. Department of Health and Human Services' “Fi-
nal Rule” establishing a regulatory framework for the OPTN
states that the goal of organ allocation is to balance “utility
and equity” using “objective and measurable medical
criteria” for individuals to be added to organ transplant
waiting lists.35 This study suggests that there is room for im-
provement in how we determine when patients should qual-
ify for the kidney transplant waitlist.
We show that choice of method to determine waitlist eli-
gibility led to clinically significant differences in qualifica-
tion time when applied to 3 diverse patient cohorts: a
cohort of waitlisted patients at 1 major U.S. academic center
and 2 national, multicenter study cohorts of CKD patients,
1 with only African Americans, and the other with pre-
dominantly whites. On average, calculated CrCl (by the
Cockcroft-Gault equation) disadvantaged patients as com-
pared with calculated GFR (by the MDRD study and
CKD-EPI equations) on the order of 1 to 2 years, which is
notable givenmedian wait times of 1.4 to 3.3 years (depend-
ing on geographic location) for deceased donor transplant
in the United States.36
Prior papers in academic journals have shown that
Cockcroft-Gault–calculated CrCl tends to overestimate renal
function as compared with MDRD study– or CKD-EPI–
calculated eGFR.17-20We have illustrated thesemathematical
relationships further based on computational analysis as de-
scribed inMethods, SDC, http://links.lww.com/TXD/A49.
Until recently, the United Network for Organ Sharing pol-
icy on kidney transplant allocation defined the threshold for
waitlist eligibility as “measured (actual urinary collection)
CrCl level or calculated GFR (Cockcroft-Gault or other reli-
able formula) less than or equal to 20mL/min.”37Our results
support the decision to remove explicit mention of then
Difference: Cockcroft-Gault vs MDRD Difference: MDRD vs CKD-EPI
1.96 (0.87, 2.83), P <0.0001 −0.07 (−0.50 to 0.17), P = 0.63
1.95 (1.51-2.43), P <0.0001 0.02 (−0.06 to 0.36), P = 0.39
1.28 (1.04-1.69), P <0.0001 −0.03 (−0.33 to 0.00), P = 0.18
ord for each patient and for the AASK and MDRD cohorts as time from first follow-up visit after 3 months
TABLE 3.
Effect of requiring persistently low renal function
Difference in medians (95% CI) between
rule 1 and rule 2, y
Percentage of patients delayed
by ≥6 mo
Percentage of patients involved with ≥1 switch
(≥6 mo) in qualification order
UCSF cohort 2.1 (1.2-3.2) a 92.3% 53.1%
AASK cohort 1.5 (1.0-1.7) a 91.5% 47.8%
MDRD cohort 0.6 (0.4-0.7) a 87.8% 40.5%
Time to waitlist qualification was defined as in Table 2. eGFR was calculated using the CKD-EPI equation. Rule 1 reflects current policy (qualification after a single eGFR≤20mL/min per 1.73 m2). Rule 2 requires
patients to demonstrate eGFR ≤20 mL/min per 1.73 m2 on 2 occurrences at least 3 months apart.
a P <0.0001.
© 2017 Wolters Kluwer Lee et al 5Cockcroft-Gault equation aswas done in themost recent pol-
icy revision in April 2017, thus removing any possible ap-
pearance of implicit endorsement of this equation over
others. However, current policy still mentions calculated
CrCl as a method for determining eligibility, and the
Cockcroft-Gault is the only equation in common use for this
purpose. We therefore suggest that calculated CrCl should be
eliminated from the rules. This reasoning is especially com-
pelling since relatively few transplant centers are likely still
using calculated CrCl after widespread adoption of auto-
matic reporting of eGFR (by the MDRD study or CKD-EPI
equations) with serum creatinine measurements.
More broadly speaking, current policy wording is problem-
atic in its apparent premise that CrCl and GFR are inter-
changeable. Although we do not have an actual data set in
which CKD patients underwent direct measures of CrCl and
GFR repeatedly over time, it is likely that usingmeasured CrCl
versus measured GFRwill also disadvantage patients to a sim-
ilar degree (ie, 1-2 years) as our analyses of using calculated
CrCl versus calculated GFR, because it is well known that
CrCl is higher than GFR due to tubular secretion of CrCl.
Further potential improvements in the policy language
may include eliminating mischaracterization of eGFR as be-
ing expressed in “mL/min.” In this context of discussing units
of measurements, perhaps it should be made explicit that if
CrCl were to be measured, the output should be expressed
in mL/min per 1.73 m2 (adjusted for body surface area), just
like for GFR, to reduce inconsistency and enhance fairness.
Notably, these issues are also relevant to other areas in
transplant medicine. For example, the United Network for
Organ Sharing Board recently approved a new simultaneous
liver-kidney policy which includes the following language:
“Candidates who are 18 years or older when registered on
the liver waiting list are eligible to receive both a liver and a
kidney from the same deceased donor when the candidate
is registered on the waiting list for both organs and meets at
least 1 of the criteria according to Table 9–11 below… At
the time of registration on the kidney waiting list, that the
candidate’s most recent measured or calculated creatinine
clearance (CrCl) or GFR is less than or equal to 30 mL/
min.”38
In addition to stimulating these types of discussions, we
hope that our analyses will provoke further examination re-
garding the underlying disease-model assumption behind
the OPTN’s rule qualifying patients based on a single reading
that is not obviously due to acute kidney injury. Because GFR
decline is not linear and monotonic,24 requiring only a single
estimate of low renal function among non–dialysis-dependent
patients may be suboptimal for identifying when patients
should qualify for the waitlist. In the cohorts studied,requiring patients to demonstrate CKD-EPI–derived eGFR
of 20 mL/min per 1.73 m2 or less on 2 occurrences at least
3 months apart delayed median time to qualification on the
order of 0.6 to 2.1 years, and a large majority (85-95%) of
each cohort was delayed by 6 months or more. More impor-
tant clinically, requiring demonstration of persistently low re-
nal function caused a substantial number (approximately
40-50%) of patients to switch the order in which they qualify
by 6 months or more. Although requiring demonstration of
low renal function on multiple measurements may not bene-
fit an individual patient, at a societal level, appropriately pri-
oritizing patients with sustained low renal function for
deceased donor transplant would better manage the imbal-
ance between kidney supply and demand. The large number
of patients who switched the order in which they qualify sug-
gests that there is room for improvement regarding the order
in which patients should be added to the waitlist.
A strength of this study is the use of 3 different cohorts.
The UCSF cohort, although small (most waitlisted patients
at UCSF are not from the faculty practice), demonstrates
the applicability of our findings to patients who were placed
on the transplant waitlist locally. Because these patients were
not enrolled in a structured research study, the frequency of
serum creatinine checks mimics how patients are monitored
before qualifying for the transplant waitlist in actual clinical
practice. Our use of the other 2 multicenter research cohorts
with different racial compositions supports the generalizabil-
ity of our results to the broader population.
Limitations of our study include that some serum creat-
inine measurements were obtained before the era of more
uniform creatinine calibration to isotope dilution mass
spectrometry–traceable references. However, because each
creatinine measurement was used for each equation within
the same person, the lack of standardization for older creati-
nine measurements should not have significantly biased our
results, which focus on within-person comparisons of
waitlist-qualification timing. The start date of our analyses
is somewhat arbitrary—but the emphasis is on the differ-
ences in the median times to qualification and not the me-
dian times themselves. We were limited in our ability to
perform subgroup analyses by demographics because the
UCSF cohort was relatively small and the AASK andMDRD
cohorts were largely racially homogeneous (all African-
American for AASK, predominantly white for MDRD).
However, our computational analysis (Figure S1, SDC,
http://links.lww.com/TXD/A49) suggests that both black
and nonblack races and both men and women were similarly
affected. Finally, we were not able to evaluate every possible
way to begin accruing time on the waitlist because we did not
have directly measured GFR (eg, assessed by exogenously
6 Transplantation DIRECT ■ 2017 www.transplantationdirect.cominjected filtration markers) or CrCl (eg, determined by
24-hour urine collection).
To conclude, we do acknowledge that there are very legit-
imate reasons for the OPTN not to dictate specific medical
practice and that programs should have some latitude on de-
fining their best measure for kidney function. However, we
suggest that the OPTN policy language be changed to “mea-
sured CrCl or estimated GFR less than or equal to 20 mL/min
per 1.73 m2” rather than “measured or calculated CrCl or
GFR less than or equal to 20 mL/min.” In other words, we
suggest that calculated CrCl be dropped because it disadvan-
tages patients, and most centers do not use that method any-
way. We also suggest that measured CrCl be quantified as
mL/min per 1.73 m2 rather than mL/min to promote fair
comparison to GFR values. Finally, we believe that some
consideration should be given to whether requiring persis-
tently reduced renal functionwill identify patients most likely
to benefit from earlier qualification for the kidney transplant
waitlist and hence expedited kidney transplant.
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